Successful intravenous immunoglobulin treatment in relapsing mog-antibody-associated disease
Publication date: Available online 15 April 2019Source: Multiple Sclerosis and Related DisordersAuthor(s): Elena Tsantes, Erica Curti, Ernesto Siena, Franco GranellaAbstractTreatment of MOG Ab-associated disease is poorly standardized: several drugs have been employed, with variable results. A 50-year-old Caucasian male was admitted to hospital in 2009, with severe acute transverse myelitis. A brain and spinal cord MRI showed multiple demyelinating lesions and cerebrospinal fluid analysis revealed no oligoclonal bands (OCBs). A diagnosis of multiple sclerosis (MS) was made. He was treated with interferon-beta 1a, then with fingolimod, and finally with rituximab. All these treatments were ineffective: he experienced several spinal and brainstem relapses, with residual disability. Finally, an empirical therapy with IVIg was started. Calling into question the diagnosis of MS, we performed anti-MOG test (positive). IVIg therapy was continued and the patient experienced only one mild relapse during a 24-month follow-up. Our patient, with an aggressive and atypical MOG Ab-associated disease, showed a very good response to longterm IVIg treatment.
Affecting 2.5 million people worldwide, multiple sclerosis (MS) is one of the main causes of acquired disability among young adults. In French West Indies (FWI), where MS has arisen from the end of the 80's, a low therapeutic response to interferons beta1 (IFN beta1) in patients of African descent, restrains the therapeutic options. Fingolimod is a Sphingosine-1-Phosphate receptor modulator whose efficacy in the treatment of MS has recently been shown in three phase III studies. Nevertheless, data are currently lacking concerning the use of Fingolimod among populations of African descent, particularly in a real-world setting.
ConclusionAZA improves relapses and disability in patients with NMOSD but this regimen is associated with relatively frequent adverse events based on limited published evidences. More well-conducted clinical trials are necessary to establish with certainty the beneficial and harmful effects of AZA in patients with NMOSD.
This article is protected by copyright. All rights reserved
ConclusionsPPMS occurs in about 10% of Polish patients with multiple sclerosis, and the first symptoms appear at around 40 years of age with the same frequency in both sexes. PPMS diagnosis takes more than twice the time for RRMS.
The mechanisms driving multiple sclerosis (MS), the most common cause of non-traumatic disability in young adults, remain unknown despite extensive research. Especially puzzling are the underlying molecular pr...
In multiple sclerosis (MS), half of affected people are unemployed within 10 years of diagnosis. The aim of this study was to assess the economic impact of MS in adult subjects with relapsing-remitting MS (RRM...
Authors: De Giglio L, Grimaldi AE, Fubelli F, Marinelli F, Pozzilli C Abstract INTRODUCTION: Decades of pharmacological research in Multiple Sclerosis (MS) led to the development of therapeutic Monoclonal Antibodies (MAbs) with many different mechanisms of action (MoA), potentially able to improve disability outcome but also determining a more complex management of patients. Areas covered: When clinicians select MS treatments, they should consider adverse events (AEs) on individual basis to minimize patients' risks. Some AEs are common and can be easily handled, but rare complications should also be taken into account...
Authors: van Mastrigt GA, Evers SM, Heerings M, Visser LH, Ruimschotel RP, Hussaarts A, Duyverman L, Valkenburg-Vissers J, Cornelissen J, Bos M, van Droffelaar M, Jongen PJ Abstract AIMS: This trial-based economic evaluation (EE) assesses from a societal perspective the cost-effectiveness of an intensive 3-day cognitive theory-based intervention (CDT), compared to care-as-usual, in patients with relapsing remitting multiple sclerosis (RRMS) and low disability (Expanded Disability Status Scale [EDDS] score
ConclusionsSince anti-MOG+ patients can have a multiphasic disease course and accumulate disability over time, high degree of suspicion and early diagnosis are of critical importance for treatment decision-making in clinical practice.AimThe aim of this case report is to enhance focus on an emerging disease spectrum among acquired CNS demyelinating disorders.
This study was conducted retrospectively examining the patient records of our MS Clinic. The patient records in 1996 were compared to those in 2016.MethodsDemographic data, duration of disease, time to diagnosis, course of the disease, EDSS scores, and whether or not patients used DMTs were recorded in both 1996 and 2016.ResultsThe mean frequency of visits were significantly higher in 1996 compared to 2016 (p=0.003). There were significantly more number of patients with CIS (p=0.004) and SPMS (p=0.001) in 1996; however, significantly less number of patients with RRMS (p